China-based Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, has announced the successful completion of an oversubscribed $100 million strategic financing round with a leading investment by Medtronic, one of the world's largest medical technology companies, alongside continued support from existing investors such as EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures.
Separately, Medtronic and Pulnovo have entered into a commercial agreement that contemplates potential future commercialisation opportunities.
This financing strengthens Pulnovo's strategic collaboration with global industry and capital partners, enhancing the company's ability to advance clinical development, execute global regulatory strategies, and expand commercial operations.
The proceeds from this financing will be used to support ongoing clinical development, global regulatory submissions, international commercialisation, and continued investment in the company's core technology platform.
Pulnovo's proprietary Pulmonary Artery Denervation (PADN) System targets a key underlying mechanism of cardiopulmonary disease and has demonstrated meaningful clinical benefits, including improvements in functional capacity and patient outcomes. To date, the company has performed approximately 1,500 PADN procedures globally and has secured regulatory approvals in seven countries, supporting its expanding international footprint. Pulnovo is advancing commercialisation across the European Union, Middle East, and China.
In the United States, Pulnovo has received FDA Breakthrough Device designation and has initiated two fully approved Investigational Device Exemption (IDE) trials, both led by Dr Gregg Stone, Senior Faculty and Professor at Mount Sinai.
